课题基金 / 基金详情

PROBING DRUG RELATED MENTAL DISORDERS OF AGING

PROBING DRUG RELATED MENTAL DISORDERS OF AGING
探索与药物相关的衰老精神障碍
批准号:
6477063
负责人:
IRA R KATZ
金额:
$46.57万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 2003-11-30

项目摘要

项目成果

IRA R KATZ的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Adverse effects of medications prescribed for elderly patients are common causes of the mental disorders of aging. Therefore, studies of the cognitive, affective, and behavioral symptoms that result from the administration of centrally-acting medications can provide information about the symptoms that characterize the toxic encephalopathies. From a practical perspective, they can provide clinicians and patients with information on the risks associated with use of the tested medications that could facilitate the prevention of disability. Accordingly, we are proposing to conduct randomized, double-blind, placebo-controlled challenge studies in which we will administer commonly prescribed medications for a period of several weeks to healthy, medically stable elderly volunteers. We will test for effects of active medications versus placebo with weekly tests of cognition, depression, other mood states, and sleepiness/alertness, and with daily self-reports of events and of both positive and negative affects. The medications to be studied were selected because they are commonly used, sufficiently safe to allow administration to elderly volunteers, and are suspected as causes of cognitive or affective toxicity. We propose two studies: Study I will compare the effects of 5 weeks of metoclopramide (up to 40 mg/day), sertraline (up to 200 mg/day), naproxen (up to 1000 mg/day), and placebo. Study II will compare 14 weeks of simvastatin (up to 20 mg/day) with placebo. Analyses will include modeling using random regression models. The hypotheses to be tested are that the medications under investigation can cause behavioral toxicity manifest by changes in cognitive performance assessed through weekly assessments; depressive or related symptoms manifest through weekly clinical interviews or self- reports on depression and behavioral rating scales; and increased negative affect and/or decreased positive affect as assessed through daily self-reports. We will also explore the impact of medications on daily reports of positive or negative events and on the relationship between daily events and daily affect.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Depression in Alzheimer's Disease Study-2(DIADS-2)
  • 批准号:
    6792773
  • 项目类别:
  • 资助金额:
    $7.7万
  • 财政年份:
    2003
  • 负责人:
    IRA R KATZ
  • 依托单位:
Depression in Alzheimer's Disease Study-2(DIADS-2)
  • 批准号:
    6851701
  • 项目类别:
  • 资助金额:
    $7.83万
  • 财政年份:
    2003
  • 负责人:
    IRA R KATZ
  • 依托单位:
Depression in Alzheimer's Disease Study-2(DIADS-2)
  • 批准号:
    6630096
  • 项目类别:
  • 资助金额:
    $7.93万
  • 财政年份:
    2003
  • 负责人:
    IRA R KATZ
  • 依托单位:
DEPRESSION AND MEDICAL CARE:AGING AND CLINICAL SETTING
  • 批准号:
    6661174
  • 项目类别:
  • 资助金额:
    $124.14万
  • 财政年份:
    2002
  • 负责人:
    IRA R KATZ
  • 依托单位: